- Home
- RIGL vs KELYB Comparison
RIGL vs KELYB Comparison
Compare RIGL & KELYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- KELYB
- Stock Information
- Founded
- RIGL 1996
- KELYB 1946
- Country
- RIGL United States
- KELYB United States
- Employees
- RIGL N/A
- KELYB N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- KELYB Professional Services
- Sector
- RIGL Health Care
- KELYB Consumer Discretionary
- Exchange
- RIGL Nasdaq
- KELYB Nasdaq
- Market Cap
- RIGL 486.4M
- KELYB 519.5M
- IPO Year
- RIGL 2000
- KELYB N/A
- Fundamental
- Price
- RIGL $17.09
- KELYB $14.00
- Analyst Decision
- RIGL Buy
- KELYB
- Analyst Count
- RIGL 5
- KELYB 0
- Target Price
- RIGL $34.80
- KELYB N/A
- AVG Volume (30 Days)
- RIGL 203.8K
- KELYB 381.0
- Earning Date
- RIGL 11-07-2024
- KELYB 02-13-2025
- Dividend Yield
- RIGL N/A
- KELYB 2.14%
- EPS Growth
- RIGL N/A
- KELYB 80.11
- EPS
- RIGL 0.22
- KELYB 1.16
- Revenue
- RIGL $157,374,000.00
- KELYB $4,372,900,000.00
- Revenue This Year
- RIGL $48.98
- KELYB N/A
- Revenue Next Year
- RIGL $14.43
- KELYB $8.21
- P/E Ratio
- RIGL $77.18
- KELYB $11.22
- Revenue Growth
- RIGL 21.65
- KELYB N/A
- 52 Week Low
- RIGL $7.48
- KELYB $14.00
- 52 Week High
- RIGL $29.82
- KELYB $25.00
- Technical
- Relative Strength Index (RSI)
- RIGL 30.82
- KELYB 21.28
- Support Level
- RIGL $16.68
- KELYB $14.20
- Resistance Level
- RIGL $19.80
- KELYB $15.50
- Average True Range (ATR)
- RIGL 1.53
- KELYB 0.01
- MACD
- RIGL -1.05
- KELYB 0.09
- Stochastic Oscillator
- RIGL 3.66
- KELYB 0.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About KELYB Kelly Services Inc. Class B
Kelly Services Inc is a provider of workforce solutions and consulting and staffing services. The company's operations are divided into five business segments namely Professional & Industrial, Science, Engineering & Technology, Education, Outsourcing & Consulting, and International. Other than OCG, each segment delivers talent through staffing services, permanent placement, or outcome-based services. OCG segment delivers talent solutions including managed service providers, payroll process outsourcing, recruitment process outsourcing, and talent advisory services. International also delivers RPO talent solutions within its local markets. The majority of revenue is derived from Professional & Industrial.